SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001636050-19-000094
Filing Date
2019-11-08
Accepted
2019-11-08 08:02:28
Documents
54
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q a09301910qaxovant.htm 10-Q 1252312
2 EXHIBIT 31.1 a093019exhibit311.htm EX-31.1 10109
3 EXHIBIT 31.2 a093019exhibit312.htm EX-31.2 10158
4 EXHIBIT 32.1 a093019exhibit321.htm EX-32.1 6204
5 EXHIBIT 32.2 a093019exhibit322.htm EX-32.2 6187
  Complete submission text file 0001636050-19-000094.txt   4154138

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT axon-20190930.xml EX-101.INS 475355
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axon-20190930.xsd EX-101.SCH 38103
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT axon-20190930_cal.xml EX-101.CAL 53149
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT axon-20190930_def.xml EX-101.DEF 182356
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT axon-20190930_lab.xml EX-101.LAB 471855
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axon-20190930_pre.xml EX-101.PRE 279863
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-37418 | Film No.: 191202148
SIC: 2834 Pharmaceutical Preparations